8/12/2019 Circulating Levels of Tumor Markers

1/1

reast cancer is most common malignant disorder in

ibyan females. It is the most dreadful disease in terms

f quality of life, in spite of heart disease being more

ommon cause of mortality here. Benign and malignant

reast disorders are very common in Libyan women

milar to other Arab countries and particularly younger

ndividuals are affected here when compared with the

western population. This could be explained by the

ttribution of various factors such as the robust

pidemiological control of infectious diseases, increase

n the average life span of the general population,

igher socio-economic status, smoking, higher

ncidence of hepatitis B and C, food fads and socio-

conomic factors. Breast cancer is one of the leading

ancers, with an earlier age of onset in Libya and 26%

f all cancers belong to the category of breast cancers

n Libya as per the Benghazi cancer registry. Almost aecade ago, Singh and Al-Sudani demonstrated that

reast cancer is one of the top ten cancers responsible

or high mortality in Libya. In another study conducted

etween 1981 and 1985, breast cancer was the most

equent type (29.8%) in females and the majority of

hese patients were of a younger age group (72.3%

elow 50 years). Almost all the patients selected for our

tudy were multiparous and were breast-feeding. A

ecent literature review by Najjar and Easson provided

vidence that the average age of onset of breast cancer

n Arab women is 48 years, almost a decade sooner

han their western counterparts and this warrants

ffective screening and management strategies. The

resent study is a case control study of tumour markers

CA 125, CA 15-3 and Carcino-embryonic antigen (CEA)

n serum of patients suffering from benign and

malignant breast disorders in Libya.

Introduction

ata on sex hormone status in 11 cases of

onfirmed carcinoma of breast patients in the age

roup ranging from 30 55 years of age have

een retrieved from the department of surgery,

th October Hospital, Benghazi, Libya. This data

compared with 8 cases of benign fibroadenosis

nd 9 age matched controls free from both

malignant and benign disorders of breast in this

tudy. Venous samples from the patients and

ontrols were tested for serum CA125, CA15-

and CEA levels by authenticated methods by

sing Cobas E 411 analyser. Statistical analysis

as done by SPSS software using Mann-

Whitney and Wilcoxon tests.

The present study has shown high levels

of CA 15-3 and CEA only in malignant

disorders of breast. This result identifies

these biomarkers as the diagnostic and

prognostic markers for carcinoma

breast. CA 125 has not shown any

significance in this study proving that it

has no significance as a biomarker in

malignant breast disorders.

Table.1

Material and Methods

ResultsReferences

There is no significant rise of CA 125 in benign

(p=0814) and malignant (p= 0.676) disorders of

breast when compared to controls. CA 15-3 was

significantly high in patients suffering from breastcancer (p= 0.019) when compared to controls

and also very significantly high when (p= 0.003)

compared with patients with benign breast

disorders. However, the levels of CA 15-3 was

not significantly high in patients with benignbreast disorders (p=0.186) when compared to

controls. The level of CEA was significantly high

in patients of breast cancer when compared to

patients of benign breast (p=0.009) disorders and

(p=0.017) controls. However, the levels of CEA is

not significantly high in patients with benignbreast disorders (p=0.634) when compared to

controls. Results are summarized in table.1

Circulating tumor markers of benign and malignant breast disorders in Libya

J. R. Peela1, S. Shakila1, S. J. Dhoipode7 A. R. Said1, H. Beloch2S. Nang2 L. T. Peela3A. M. Jarari4S.O.Alsaeoti5H. El Awamy4N. M. Jarari6M. J. Kadeer4

1. Department of Biochemistry, Faculty of Medicine,Quest International University Perak, Ipoh, Malaysia

2. Faculty of Medicine,Quest International University Perak, Ipoh, Malaysia,

3. Great Eastern Medical School, Srikakulam, India,

4. Department of Biochemistry, Faculty ofMedicine,University of Benghazi, Benghazi, Libya.

5. Department of Surgery, Faculty of Medicine,University of Benghazi, Benghazi, Libya.

6. Department of Pharmacology, Faculty ofMedicine,University of Benghazi, Benghazi, Libya.

7.Department of Pharmacology, Guardian college of Dental Sciences and research centre,Ambernath,Thane,Maharastra,India .

Anim JT (1990) Breast cancer in Arab women: A

review. Emirates Med J 8: 189-195.

Elattar I (2005) Cancer in the Arab World:

Magnitude of the Problem. UICC March 21-25.El Mistiri M, Verdecchia A, Rashid I, El Sahli N, El

Mangush M, et al. (2007) Cancer incidence in

eastern Libya: the first report from the Benghazi

Cancer Registry, 2003. Int J Cancer 120: 392-

397.

Singh R, Al-Sudani OE (2001) Cancer mortality inBenghazi, Libyan Arab Jamahiriya, 1991-96.

East Mediterr Health J 7: 255-273.

Akhtar SS, Abu Bakr MA, Dawi SA, Huq IU

(1993) Cancer in Libya--a retrospective study(1981-1985). Afr J Med Med Sci 22: 17-24.Najjar H, Easson A (2010) Age at diagnosis of

breast cancer in Arab nations. Int J Surg 8:448-

452

Bielecka-Dbrowa A, Hannam S, Rysz J, Banach

M (2011) Malignancy- Associated Dyslipidemia.Open Cardiovasc Med J 5: 35-40.

Cheung KL, Graves CR, Robertson JF. Tumour

marker measurements in the diagnosis and

monitoring of breast cancer. Cancer Treat Rev

2000;26:91102.

Molina R, Filella X, Alicarte J, Zanon G, Pahisa J,Munoz M, et al. Prospective evaluation of CEA

and CA 15.3 in patients with locoregional breast

cancer. Anticancer Res 2003;23:10351041.

Gion M, Boracchi P, Dittadi R, Biganzoli E,

Peloso L, Mione R, et al. Prognostic role ofserum CA15.3 in 362 node-negative breast

cancers. An old player for a new game. Eur J

Cancer 2002;38:11811188.

Ebeling FG, Stieber P, Untch M, Nagel D,

Konecny GE, Schmitt UM, et al. Serum CEA

and CA 15-3 as prognostic factors in primarybreast cancer. Br J Cancer 2002;86:1217

1222.

Duffy MJ, Duggan C, Keane R, Hill AD,

McDermott E, Crown J, OHiggins N. High

preoperative CA 15-3 concentrations predict

adverse outcome in node-negative and node-positive breast cancer: study of 600 patients

with histologically confirmed breast cancer. Clin

Chem 2004;50:559563.

Molina R, Zanon G, Filella X, Moreno F, Jo J,

Daniels M, et al. Use of serial carcinoembryonicantigen and CA 15.3 assays in detecting

relapses in breast cancer patients. Breast

Cancer Res Treat 1995;36:4148.

Soletormos G, Nielsen D, Schioler V, Mouridsen

H, Dombernowsky P. Monitoring differentstages of breast cancer using tumour markers

CA 15-3, CEA and TPA. Eur J Cancer

2004;40:481486.

Molina R, Jo J, Filella X, Zanon G, Pahisa J,

Munoz M, et al. c-erbB-2 oncoprotein, CEA,

and CA 15.3 in patients with breast cancer:prognostic value. Breast Cancer Res Treat

1998;51:109119.

TypeCA125 CA15-3 CEA

Carcinoma

Breast

No of cases 11 11 11

Mean 90.97 92.90 12.53

Std Deviation 232.15 109.58 20.30Controls

No of cases 9 99

Mean 19.58 17.76 1.92

Std Deviation 16.88 6.34 .90

Fibroadenosis No of cases 8 8

8

Mean 17.92 13.38 1.57

Std. Deviation 15.77 4.36 .387

Conclusion